All In Biotech

BLA 103948 · Genzyme

Lemtrada

Alemtuzumab · Injection, Intravenous · CD52-directed Cytolytic Antibody

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

May 7, 2001

Approved uses

4

Original approval plus efficacy supplements

Registered trials

350

27 Phase 3, 30 recruiting

FAERS reports

19,365

16,665 serious, 2,947 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CYTOPENIAS, INFUSION-RELATED REACTIONS, AND INFECTIONS WARNING: CYTOPENIAS, INFUSION-RELATED REACTIONS, AND INFECTIONS See full prescribing information for complete boxed warning. Serious, including fatal, cytopenias, infusion-related reactions, and infections can occur (5.1–5.3). Limit doses to 30 mg (single) and 90 mg (cumulative weekly); higher doses increase risk of pancytopenia. ( 2.1 ) Escalate dose gradually and monitor patients during infusion. Withhold therapy for Grade 3 or 4 infusion-related reactions. ( 5.2 ) Administer prophylaxis against Pneumocystis jirovecii pneumonia (PCP) and herpes virus infections. ( 2.2 , 5.3 ) Cytopenias : Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving CAMPATH. Single doses of CAMPATH greater than 30 mg or cumulative doses...

What it is approved for

From the label in effect Nov 5, 2025.

CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). ( 1 )

Mechanism: CAMPATH binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34+ cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of CAMPATH to the leukemic cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 28, 2018 Supplement 5160 · Efficacy LabelLetter
  • Nov 14, 2014 Supplement 5139 · Efficacy
  • Sep 19, 2007 Supplement 5070 · Efficacy · priority review OrphanLetter
  • May 7, 2001 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
3 products under this application
  • LEMTRADA · ALEMTUZUMAB 12MG/1.2ML (10MG/ML) · INJECTABLE, INJECTION · Prescription
  • CAMPATH · ALEMTUZUMAB 10MG/ML · VIAL, INTRAVENOUS · Prescription
  • CAMPATH · ALEMTUZUMAB 30MG/ML · VIAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alemtuzumab" as an intervention, any sponsor and status, largest first.

All 350 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache1,906
  • fatigue1,874
  • pyrexia1,784
  • off label use1,698
  • rash1,200
  • nausea1,190
  • drug ineffective1,032
  • dyspnoea985
  • asthenia942
  • multiple sclerosis relapse923
  • lymphocyte count decreased879
  • cytomegalovirus infection839

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004153
2005150
2006150
2007189
2008336
2009373
2010363
2011704
2012320
2013427
2014486
2015985
20161,627
20171,750
20182,274
20192,380
20201,690
20211,288
20221,072
2023849
2024738
2025635
2026425

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Lemtrada (Alemtuzumab) · HCPCS J0202

2024 spending

$2.7M

Beneficiaries

25

102 claims

Per beneficiary

$107,721

2024 ASP limit $2,339.61 per unit

View as table
YearSpending
2020$12,586,313
2021$5,626,186
2022$4,021,632
2023$3,660,335
2024$2,693,035

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 463 on PubMed

Sponsor: Sanofi · Also marketed as Campath

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.